Out-Of-Specification (OOS) Result Handling Continues as Dominant Theme in FDA Warning Letters
20/6/2011
Giving adequate attention to out-of-specification (OOS) results in batch release decision making and investigation follow up continues as the dominant theme in 2011 in GMP warning letters issued to foreign companies by FDA’s drug and biologic compliance offices. More ...
Author: Greer Deal, Director of Global Regulatory Services (GRS)